BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 27,000 Shares of Company Stock

October 10, 2026 by InsiderTrades.com

Key Points

CEO insider selling: Ugur Sahin sold 27,000 BioNTech shares for approximately $2.49 million under a pre-arranged Rule 10b5-1 plan, reducing his direct ownership by 42.72% to 36,209 shares. The sales followed several additional large disposals in recent weeks.
Weak quarterly performance: BioNTech reported a quarterly loss of $2.53 per share and revenue of $122.31 million, down 59.5% year over year and below analysts’ $180.18 million estimate. Analysts expect the company to post a full-year loss.
Analysts remain moderately bullish: BioNTech has a consensus “Moderate Buy” rating and an average price target of $125.69, compared with a recent share price of $96.96, despite several analysts lowering their targets.

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 27,000 shares of the stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $92.31, for a total value of $2,492,370.00. Following the completion of the transaction, the chief executive officer directly owned 36,209 shares in the company, valued at approximately $3,342,452.79. This represents a 42.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

4 Reasons Pfizer Could Be a Value Play You Can't Miss

Ugur Sahin also recently made the following trade(s):

On Friday, October 9th, Ugur Sahin sold 36,209 shares of BioNTech stock. The stock was sold at an average price of $95.37, for a total value of $3,453,252.33.
On Wednesday, October 7th, Ugur Sahin sold 24,000 shares of BioNTech stock. The shares were sold at an average price of $95.86, for a total value of $2,300,640.00.
On Tuesday, October 6th, Ugur Sahin sold 21,000 shares of BioNTech stock. The shares were sold at an average price of $96.81, for a total transaction of $2,033,010.00.
On Monday, October 5th, Ugur Sahin sold 72,000 shares of BioNTech stock. The shares were sold at an average price of $97.23, for a total transaction of $7,000,560.00.
On Thursday, October 1st, Ugur Sahin sold 17,000 shares of BioNTech stock. The stock was sold at an average price of $97.46, for a total transaction of $1,656,820.00.
On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The stock was sold at an average price of $98.12, for a total transaction of $3,139,840.00.
On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.47, for a total transaction of $3,347,980.00.
On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The shares were sold at an average price of $98.69, for a total transaction of $2,664,630.00.
On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The shares were sold at an average price of $98.99, for a total transaction of $3,860,610.00.
On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total transaction of $2,982,000.00.

BioNTech Stock Up 5.3%

BNTX opened at $96.96 on Friday. The firm's 50 day simple moving average is $99.17 and its two-hundred day simple moving average is $95.17. The company has a market capitalization of $24.52 billion, a PE ratio of -12.38 and a beta of 1.25. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01.

Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.40) by ($0.13). The business had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company's revenue was down 59.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.60) EPS. As a group, equities analysts forecast that BioNTech SE Sponsored ADR will post -6.37 EPS for the current year.

Analyst Ratings Changes

A number of analysts have commented on the company. Canaccord Genuity Group reduced their price target on BioNTech from $142.00 to $136.00 and set a "buy" rating for the company in a research report on Monday, August 31st. UBS Group reiterated a "buy" rating on shares of BioNTech in a research note on Wednesday, September 16th. Morgan Stanley reduced their target price on shares of BioNTech from $115.00 to $114.00 and set an "overweight" rating for the company in a report on Wednesday. Berenberg Bank set a $140.00 target price on shares of BioNTech in a report on Wednesday, September 16th. Finally, Citigroup decreased their target price on shares of BioNTech from $130.00 to $125.00 and set a "buy" rating on the stock in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, BioNTech currently has a consensus rating of "Moderate Buy" and an average target price of $125.69.

Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?

View Our Latest Stock Report on BioNTech

Institutional Investors Weigh In On BioNTech

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Flossbach Von Storch SE purchased a new position in shares of BioNTech in the second quarter valued at about $207,142,000. Bank of America Corp DE boosted its stake in shares of BioNTech by 22.6% in the first quarter. Bank of America Corp DE now owns 903,029 shares of the company's stock worth $80,261,000 after acquiring an additional 166,432 shares during the period. First Trust Advisors LP grew its position in shares of BioNTech by 116.0% during the first quarter. First Trust Advisors LP now owns 839,991 shares of the company's stock worth $74,658,000 after purchasing an additional 451,124 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of BioNTech during the second quarter worth about $39,385,000. Finally, SEB Asset Management AB purchased a new stake in shares of BioNTech during the first quarter worth about $17,804,000. 15.52% of the stock is owned by institutional investors.

Key BioNTech News

Here are the key news stories impacting BioNTech this week:

Positive Sentiment: Biotech-sector momentum offered a modest tailwind after Moderna’s inclusion in the Nasdaq-100 triggered a sharp move in its shares, while BioNTech also traded higher alongside other major vaccine companies. Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
Neutral Sentiment: Argus initiated coverage with a Hold rating, adding a cautious view but no immediate change to the company’s fundamentals. Argus coverage reference
Neutral Sentiment: A report stating that short interest totaled zero shares implies no measurable short-squeeze pressure. The figure may reflect a reporting or data issue and should be interpreted cautiously.
Negative Sentiment: CEO Ugur Sahin sold 36,209 shares for approximately $3.45 million on October 9 and another 27,000 shares for about $2.49 million on October 8. The transactions were executed under a pre-arranged Rule 10b5-1 plan, which reduces their significance as discretionary signals, but the sales substantially reduced his direct ownership. BioNTech CEO SEC filing
Negative Sentiment: The latest quarterly results showed continuing commercial pressure: revenue fell 59.5% year over year to $122.31 million, below the $180.18 million consensus estimate, while the company reported a loss of $2.53 per share. Analysts expect a full-year loss, underscoring the need for BioNTech’s pipeline to offset declining COVID-19 vaccine revenue.

BioNTech Company Profile

(Get Free Report)

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company's research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.